RU2009104312A - Наночастицы типа "ядро-оболочка" для терапии и диагностических целей - Google Patents
Наночастицы типа "ядро-оболочка" для терапии и диагностических целей Download PDFInfo
- Publication number
- RU2009104312A RU2009104312A RU2009104312/15A RU2009104312A RU2009104312A RU 2009104312 A RU2009104312 A RU 2009104312A RU 2009104312/15 A RU2009104312/15 A RU 2009104312/15A RU 2009104312 A RU2009104312 A RU 2009104312A RU 2009104312 A RU2009104312 A RU 2009104312A
- Authority
- RU
- Russia
- Prior art keywords
- core
- shell
- shell type
- nanoparticles
- type nanoparticle
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1878—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating
- A61K49/1881—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating wherein the coating consists of chelates, i.e. chelating group complexing a (super)(para)magnetic ion, bound to the surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nanotechnology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Cardiology (AREA)
- Radiology & Medical Imaging (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
1. Наночастица типа «ядро-оболочка», в которой вещество ядра имеет более широкую запрещенную зону, чем вещество оболочки, в которой вещество ядра и вещество оболочки содержат одну и ту же анионную решетку и в которой поверхность наночастицы ядро-оболочка снабжена биологически совместимым веществом. ! 2. Наночастица типа «ядро-оболочка» по п.1, в которой низшие энергетические уровни Ферми и для электрона, и для дырок в ядре являются более широкими, чем в оболочке. ! 3. Наночастица типа «ядро-оболочка» по п.1, в которой комбинацию вещества ядра/оболочки выбирают из ZnS/CdS, GaN/InN, GaP/InP, Y2O3/In2O3, WO3/MoO3, ZrO2/CeO2. !4. Наночастица типа «ядро-оболочка» по п.1, конъюгированная с нацеливающим веществом. ! 5. Наночастица типа «ядро-оболочка» по п.1, в которой поверхность наночастицы типа «ядро-оболочка» снабжена МРТ - активным ионным комплексом или активным агентом МРТ. ! 6. Наночастица типа «ядро-оболочка» по п.5, в которой поверхность снабжена нуклидами. ! 7. Наночастица типа «ядро-оболочка» по п.6, в которой нуклид выбирают из I23I, 67Ga, 99mTC, 18F и 11C. ! 8. Наночастица типа «ядро-оболочка» по одному из пп.1 или 2 для использования в качестве медицинского или терапевтического средства и/или для интраскопии. ! 9. Применение наночастиц типа «ядро-оболочка» по одному из пп.1-7 для приготовления лекарственной или терапевтической композиции. ! 10. Применение по п.9 наночастиц типа «ядро-оболочка» для приготовления композиции для фотодинамической терапии. ! 11. Применение по одному из пп.9 или 10 наночастиц типа «ядро-оболочка» в комбинации с другими химическими лекарствами или фармацевтическими препаратами. ! 12. Способ получения наночастиц по одному из пп.1-7, в котор
Claims (12)
1. Наночастица типа «ядро-оболочка», в которой вещество ядра имеет более широкую запрещенную зону, чем вещество оболочки, в которой вещество ядра и вещество оболочки содержат одну и ту же анионную решетку и в которой поверхность наночастицы ядро-оболочка снабжена биологически совместимым веществом.
2. Наночастица типа «ядро-оболочка» по п.1, в которой низшие энергетические уровни Ферми и для электрона, и для дырок в ядре являются более широкими, чем в оболочке.
3. Наночастица типа «ядро-оболочка» по п.1, в которой комбинацию вещества ядра/оболочки выбирают из ZnS/CdS, GaN/InN, GaP/InP, Y2O3/In2O3, WO3/MoO3, ZrO2/CeO2.
4. Наночастица типа «ядро-оболочка» по п.1, конъюгированная с нацеливающим веществом.
5. Наночастица типа «ядро-оболочка» по п.1, в которой поверхность наночастицы типа «ядро-оболочка» снабжена МРТ - активным ионным комплексом или активным агентом МРТ.
6. Наночастица типа «ядро-оболочка» по п.5, в которой поверхность снабжена нуклидами.
7. Наночастица типа «ядро-оболочка» по п.6, в которой нуклид выбирают из I23I, 67Ga, 99mTC, 18F и 11C.
8. Наночастица типа «ядро-оболочка» по одному из пп.1 или 2 для использования в качестве медицинского или терапевтического средства и/или для интраскопии.
9. Применение наночастиц типа «ядро-оболочка» по одному из пп.1-7 для приготовления лекарственной или терапевтической композиции.
10. Применение по п.9 наночастиц типа «ядро-оболочка» для приготовления композиции для фотодинамической терапии.
11. Применение по одному из пп.9 или 10 наночастиц типа «ядро-оболочка» в комбинации с другими химическими лекарствами или фармацевтическими препаратами.
12. Способ получения наночастиц по одному из пп.1-7, в котором вещество оболочки наращивают эпитаксиально на веществе ядра.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06116923 | 2006-07-10 | ||
EP06116923.1 | 2006-07-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2009104312A true RU2009104312A (ru) | 2010-08-20 |
Family
ID=38805581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2009104312/15A RU2009104312A (ru) | 2006-07-10 | 2007-07-02 | Наночастицы типа "ядро-оболочка" для терапии и диагностических целей |
Country Status (7)
Country | Link |
---|---|
US (1) | US20090191128A1 (ru) |
EP (1) | EP2040752A2 (ru) |
JP (1) | JP2009544584A (ru) |
CN (1) | CN101489590A (ru) |
BR (1) | BRPI0713940A2 (ru) |
RU (1) | RU2009104312A (ru) |
WO (1) | WO2008007290A2 (ru) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8951561B2 (en) | 2007-08-06 | 2015-02-10 | Duke University | Methods and systems for treating cell proliferation disorders using plasmonics enhanced photospectral therapy (PEPST) and exciton-plasmon enhanced phototherapy (EPEP) |
JP2008289971A (ja) * | 2007-05-23 | 2008-12-04 | Toyota Motor Corp | コアシェル構造体及びその製造方法並びに当該コアシェル構造体を含む排ガス浄化用触媒 |
US9232618B2 (en) * | 2007-08-06 | 2016-01-05 | Immunolight, Llc | Up and down conversion systems for production of emitted light from various energy sources including radio frequency, microwave energy and magnetic induction sources for upconversion |
WO2013009688A1 (en) | 2011-07-08 | 2013-01-17 | Bourke Frederic A | Phosphors and scintillators for light stimulation within a medium |
JP5967935B2 (ja) | 2008-04-04 | 2016-08-10 | イミュノライト・エルエルシー | insituでのフォトバイオモデュレーションのための非侵襲性システムおよび方法 |
EP2130553A1 (en) * | 2008-06-05 | 2009-12-09 | Nanobiotix | Inorganic nanoparticles of high density to destroy cells in-vivo |
EP2421376A4 (en) * | 2009-04-21 | 2016-04-27 | Immunolight Llc | NON-INVASIVE ENERGY UPGRADING METHODS AND SYSTEMS FOR IN-SITU PHOTO BODY MODULATION |
US9034204B2 (en) | 2009-12-16 | 2015-05-19 | The Regents Of The University Of California | Gold coating of rare earth nano-phosphors and uses thereof |
US10175170B2 (en) | 2010-12-16 | 2019-01-08 | The Regents Of The University Of California | Metal coating of rare earth nano-phosphors and uses thereof |
WO2013087920A1 (en) | 2011-12-16 | 2013-06-20 | Nanobiotix | Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof |
US8591773B2 (en) * | 2012-02-09 | 2013-11-26 | Huawei Technologies Co., Ltd. | Heterojunction nano material, negative pole piece of lithium ion battery, and lithium ion battery |
CN102569763A (zh) * | 2012-02-09 | 2012-07-11 | 华为技术有限公司 | 异质结纳米材料、锂离子电池负极极片及锂离子电池 |
WO2015164780A1 (en) * | 2014-04-25 | 2015-10-29 | The Regents Of The University Of Michigan | Nanoparticle therapy in cancer |
CN107735357B (zh) * | 2014-11-20 | 2021-11-23 | Z·巴达什 | 氧化剂的制备 |
AU2016269146B2 (en) | 2015-05-28 | 2021-01-28 | Nanobiotix | Nanoparticles for use as a therapeutic vaccine |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020127224A1 (en) * | 2001-03-02 | 2002-09-12 | James Chen | Use of photoluminescent nanoparticles for photodynamic therapy |
CA2453450A1 (en) * | 2001-07-20 | 2003-11-06 | Quantum Dot Corporation | Luminescent nanoparticles and methods for their preparation |
US7939170B2 (en) * | 2002-08-15 | 2011-05-10 | The Rockefeller University | Water soluble metal and semiconductor nanoparticle complexes |
ATE512115T1 (de) * | 2003-01-22 | 2011-06-15 | Univ Arkansas | Monodisperse nanokristalle mit kern/schale und anderen komplexen strukturen sowie herstellungsverfahren dafür |
CA2563619A1 (en) * | 2004-04-20 | 2005-11-03 | Emory University | Multimodality nanostructures, methods of fabrication thereof, and methods of use thereof |
-
2007
- 2007-07-02 RU RU2009104312/15A patent/RU2009104312A/ru not_active Application Discontinuation
- 2007-07-02 EP EP07789853A patent/EP2040752A2/en not_active Withdrawn
- 2007-07-02 US US12/307,786 patent/US20090191128A1/en not_active Abandoned
- 2007-07-02 JP JP2009519018A patent/JP2009544584A/ja active Pending
- 2007-07-02 BR BRPI0713940-3A patent/BRPI0713940A2/pt not_active Application Discontinuation
- 2007-07-02 CN CNA2007800260628A patent/CN101489590A/zh active Pending
- 2007-07-02 WO PCT/IB2007/052557 patent/WO2008007290A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
JP2009544584A (ja) | 2009-12-17 |
WO2008007290A3 (en) | 2008-06-26 |
CN101489590A (zh) | 2009-07-22 |
EP2040752A2 (en) | 2009-04-01 |
BRPI0713940A2 (pt) | 2012-12-04 |
WO2008007290A2 (en) | 2008-01-17 |
US20090191128A1 (en) | 2009-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2009104312A (ru) | Наночастицы типа "ядро-оболочка" для терапии и диагностических целей | |
Fu et al. | Stimuli-responsive small-on-large nanoradiosensitizer for enhanced tumor penetration and radiotherapy sensitization | |
Huang et al. | A metabolic multistage glutathione depletion used for tumor-specific chemodynamic therapy | |
Li et al. | Gram-scale synthesis of highly biocompatible and intravenous injectable hafnium oxide nanocrystal with enhanced radiotherapy efficacy for cancer theranostic | |
Su et al. | High biocompatible ZIF-8 coated by ZrO2 for chemo-microwave thermal tumor synergistic therapy | |
Feng et al. | Iridium nanocrystals encapsulated liposomes as near-infrared light controllable nanozymes for enhanced cancer radiotherapy | |
Al-Yasiri et al. | Mangiferin functionalized radioactive gold nanoparticles (MGF-198 AuNPs) in prostate tumor therapy: green nanotechnology for production, in vivo tumor retention and evaluation of therapeutic efficacy | |
Song et al. | Emerging nanotechnology and advanced materials for cancer radiation therapy | |
Zhu et al. | Nanoenzyme-augmented cancer sonodynamic therapy by catalytic tumor oxygenation | |
US20200276230A1 (en) | Particles for the treatment of cancer in combination with radiotherapy | |
Zhang et al. | Positive feedback nanoamplifier responded to tumor microenvironments for self-enhanced tumor imaging and therapy | |
Chen et al. | Radionuclide 131I labeled reduced graphene oxide for nuclear imaging guided combined radio-and photothermal therapy of cancer | |
DK2749292T3 (en) | TUMOR chemotherapeutic drug DEFINITION AND MANUFACTURING METHOD THEREOF | |
Munaweera et al. | Chemoradiotherapeutic magnetic nanoparticles for targeted treatment of nonsmall cell lung cancer | |
Zhang et al. | Complete tumor response following intratumoral 32P BioSilicon on human hepatocellular and pancreatic carcinoma xenografts in nude mice | |
Yao et al. | Albumin-templated Bi2Se3–MnO2 nanocomposites with promoted catalase-like activity for enhanced radiotherapy of cancer | |
Chen et al. | Biomimetic nanotheranostics camouflaged with cancer cell membranes integrating persistent oxygen supply and homotypic targeting for hypoxic tumor elimination | |
Liu et al. | Advances of nanomedicine in radiotherapy | |
Liu et al. | Glutathione-responsive biodegradable core–shell nanoparticles that self-generate H2O2 and deliver doxorubicin for chemo–chemodynamic therapy | |
CN106619715A (zh) | 氨基酸修饰的金属富勒烯水溶性纳米颗粒在制备肿瘤血管阻断剂中的应用 | |
Mirjolet et al. | Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model | |
JP2015057409A (ja) | 多形膠芽腫の治療のためのマシテンタンを含有する組み合わせ剤 | |
Zhang et al. | A bioenvironment-responsive versatile nanoplatform enabling rapid clearance and effective tumor homing for oxygen-enhanced radiotherapy | |
Ding et al. | Multifunctional magnetic nanoagents for bioimaging and therapy | |
Wang et al. | Enzyme‐Powered Micro/Nanomotors for Cancer Treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20100705 |